Ardelyx's Phase 3 trial to treat high phosphorusemia has reached its end

recently, Ardelyx announced that it is working on the drug Tenapanor, which reaches primary and all secondary endpoints in a critical Phase 3 trial for high phosphorusemia in dialysis patients.Studies have shown that Tenapanor is used in association with phosphate adhesives to significantly reduce phosphate levels in the patient's blood.About Tenapanor Ardelyx's new drug, Tenapanor, is an inhibitor of the sodium ion transport protein NHE3 in the gastrointestinal tract, which reduces the amount of sodium ions the gastrointestinal tract takes from food, thereby increasing the concentration of protons in gastrointestinal cells.Tenapanor's inhibition of sodium ions and phosphate absorption is selective and does not affect the absorption of other ions, molecules and nutrients in the intestines.Tenapanor is a small pill that is easier for patients to take than phosphate adhesives.Once approved, Tenapanor could be the basic therapy for patients on CKD dialysis with elevated blood phosphorus concentrations, Ardelyx said.A totalCKD patients who received hemodialysis participated in the randomized double-blind Phase 3 trial, the study said. Although these patients were treated with stable phosphate adhesives, blood phosphorus concentrations were ≥5.5 mg/dL at screening and ≤10.0 mg/dL.test results showed that the combined treatment of Tenapanor and phosphate adhesive significantly reduced blood phosphorus concentration compared to the individual treatment of phosphate adhesives, and that patients with about twice the blood phosphorus concentrations reached the <5.5 mg/dL blood phosphorus concentration target per week.addition, Tenapanor has demonstrated good safety and tolerance. (Drug Information Network)